Images are for illustrative purposes only.

Prostamax

Prostamax is the tetrapeptide Lys-Glu-Asp-Pro (KEDP), characterized within the Khavinson series as the bioregulator for prostatic and urogenital tissue. It is the only compound in the series oriented toward the prostate.

Structurally it belongs to the KED group rather than the more common AED group, and it differs from the pancreatic peptide Pancreagen (KEDW) by a single terminal residue, proline in place of tryptophan. That two peptides separated by one amino acid are described for entirely different organs is a recurring point of discussion around the organ-specificity hypothesis behind the class. Prostamax shares the KED core with Vesugen and Testagen (KED) and with Livagen (KEDA). Cell-based studies from the originating laboratory examine markers of prostate epithelial cell function, chromatin structure, and urogenital-tissue gene expression. The evidence base is preclinical and concentrated in a single research group.

Supplied as a lyophilized 10-vial 20mg kit for in vitro research use only.